Summit Therapeutics (SMMT) Retained Earnings (2018 - 2026)

Summit Therapeutics (SMMT) has 9 years of Retained Earnings data on file, last reported at $3.3 billion in Q2 2026.

• Quarterly Retained Earnings rose 58.44% year-over-year to $3.3 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.3 billion (up 58.44% YoY) and the FY2025 annual result came in at $2.9 billion, up 84.44% from the prior year.
• Retained Earnings improved to $3.3 billion in Q2 2026, from $3.0 billion in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $3.3 billion in Q2 2026 to a low of $388.3 million in Q1 2022.
• A 5-year average of $1.5 billion and a median of $1.2 billion in 2024 frame the typical range for Retained Earnings.
• Annual changes were most pronounced in 2023 — Retained Earnings jumped 170.03% — and 2024, when it grew 2.65%.
• Tracing SMMT's Retained Earnings over 5 years: stood at $504.8 million in 2022, then surged by 111.26% to $1.1 billion in 2023, then jumped by 49.87% to $1.6 billion in 2024, then jumped by 84.44% to $2.9 billion in 2025, then grew by 12.76% to $3.3 billion in 2026.
• The last three Retained Earnings figures came in at $3.3 billion (Q2 2026), $3.0 billion (Q1 2026), and $2.9 billion (Q4 2025), per Business Quant data.